Abstract: Provided is an optical member where at least a layer having polyimide as a main component and a layer having a textured structure arising from a crystal containing aluminum oxide as a main component are stacked in this order. The polyimide includes a silane group in a side chain via an amide bond.

Abstract: A removable molding tab facilitates loading component parts into a mold by providing a body with holding configurations suitable to releasably secure the component parts in mold ready positions. The component parts are loaded into a mold as a preassembly with the removable tab. The tab is removed after the component parts are placed into the mold.

Abstract: A thermoplastic polymer composition with a tertiary blend of a carbon dioxide-derived polymer, a thermoplastic cellulose derivative, and a thermoplastic compatibilizer is described. The composition can be melt-processed into flexible, thin films that have fine nano-scale structural features in both the cross-directional and machine-directional orientations, for use in various products. The films, which are made from relatively brittle materials, exhibit a greater degree of ductility, elongation capacity, and strength than the primary, original component materials as binary-blends from which the film is made.

Abstract: Disclosed is a polyamide resin film which has excellent dimensional stability with respect to moisture absorption, excellent mechanical characteristics and sliding properties under high temperature and high humidity conditions, and excellent handling properties. Specifically disclosed is a biaxially stretched polyamide resin film, to which 0.3-10% by weight of an inorganic material including a layered compound is added. The biaxially stretched polyamide resin film is characterized in that the layered compound is in-plane oriented, and that the film has a haze of 1.0-20%, an elastic modulus in the longitudinal direction of 1.7-3.5 GPa at a relative humidity (RH) of 35%, a surface roughness (Sa) of 0.01-0.1 ?m, and a coefficient of static friction (F/B) of 0.3-1.0 at a normal stress of 0.5 N/cm2.

Abstract: A reinforcing underlayment including dry uniform particles evenly applied to a wet bonding material layer on a surface of a substrate. The substrate, including the layers, is then cured to harden the one or more of the layers. A final coating or topcoat is applied to the cured surface of the substrate. The dry particles are evenly distributed onto the bonding material layer creating a uniform surface for subsequent coatings. The dry particles increase the strength of the liquid coatings increasing solid particle density within the coating system and thereby imparting properties not available for the liquid coatings. The present invention enables a user to easily introduce very heavy, dense, strong particles into a liquid coating and allows the user to apply very dense, heavy particles into and onto a wet bonding material layer followed by a subsequent wet topcoat layer which is cured as one contiguous material with reinforcement and underlayment strengthening coming from the added, dry particles.

Abstract: An abrasive article includes a backing having a major surface, an adhesion promoting layer overlying the major surface of the backing, and a make layer directly contacting the adhesion promoting layer. The adhesion promoting layer has a thickness of at least about 10 microns and is formed of a polar thermoplastic material, a cross-linkable polymer, or blends thereof.

Abstract: Packaging produced from a thermoplastic film of which the ends are placed so that they abut, said film being composed of several layers, including at least a first weldable layer and a second layer of which the butt-welding is only partial or non-existent, and at least one thin strip covering said ends and being directly attached to one of the faces of the second layer, the difference in the melting point between the first layer and the other layer or layers being greater than 20° C.

Abstract: Human lymphocyte-associated cell surface protein LAM-1, which includes domains homologous with binding domains of animal lectins, growth factors, and C3/C4 binding proteins, and the cDNA encoding LAM-1, are described. Antagonists to LAM-1 are used in a method of treating a human patient suffering from a lymphocyte-mobilizing condition which involves administering a therapeutic amount of the antagonist in a non-toxic pharmaceutical carrier substance. Additionally, antibodies that bind human LAM-1 and inhibit cellular adhesion, migration or infiltration into tissues are described.

Abstract: The present invention provides the amio acid of a protein that inhibits cellular apoptosis, herein termed the Survivin protein and nucleic acid molecules that encode Survivin. Based on this disclosure, the present invention provides isolated Survivin protein, isolated Survivin encoding nucleic acid molecules, methods of isolating other members of the Survivin family of proteins, methods for identifying agents that block Survivin mediated inhibition of cellular apoptosis, methods of using agents that block Survivin mediated inhibition or Survivin expression to modulate biological and pathological processes, and methods of assaying Survivin activity.

Abstract: The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject invention further provides an isolated antibody and a purified preparation of polyclonal and monoclonal antibodies which are specifically immunoreactive with a p27 protein. The subject invention further provides a kit for detecting a p27 protein.

Abstract: The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.

Abstract: Antigens are derived from the tandem repeat sequence of the core protein of a human polymorphic epithelial mucin. These antigens include a core protein epitope which is recognized by certain antibodies which also bind certain carcinoma antigens, but not fully processed HPEM glycoprotein as produced by the normal lactating human mammary gland.

Abstract: Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.

Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.

Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.

Abstract: B-Cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

Abstract: Methods of grading tumors and prognosticating survival rates of cancer patients by determination of p27 expression levels in tissues samples from tumors are provided.

Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.

Abstract: A novel human oncogene termed polyhomeotic 1 is disclosed. The human polyhomeotic 1 gene and protein can be used, inter alia, as a diagnostic tool for neoplastic disorders. The gene can also be used to identify a p13 region of human chromosome 12.

Abstract: The present invention relates to the relation of the TMPRSS2 gene to human cancers and its use in the diagnosis and prognosis of human cancer. The invention also relates to the therapy of human cancers which have a mutation in the TMPRSS2 gene, including gene therapy, protein replacement therapy and protein mimetics. Finally, the invention relates to the screening of drugs for cancer therapy.